Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 217, Issue 9, Pages -Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20200785
Keywords
-
Categories
Funding
- National Institutes of Health [RF1AG05148501, R21 AG059176, RF1 AG059082]
- Cure Alzheimer's Fund
Ask authors/readers for more resources
TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases Alzheimer's disease (AD) risk. In mouse models of amyloid beta (A beta) accumulation, defective TREM2 function affects microglial response to A beta plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate for AD therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available